Ignite Creation Date:
2025-12-25 @ 3:02 AM
Ignite Modification Date:
2026-03-05 @ 9:55 PM
Study NCT ID:
NCT04255433
Status:
COMPLETED
Last Update Posted:
2025-08-24
First Post:
2020-02-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Sponsor:
Eli Lilly and Company
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Type 2 Diabetes Mellitus | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Glucose Metabolism Disorders | View |
| None | Metabolic Diseases | View |
| None | Diabetes Mellitus | View |
| None | Diabetes Mellitus, Type 2 | View |
| None | Endocrine System Diseases | View |
| None | Hypoglycemic Agents | View |
| None | Physiological Effects of Drugs | View |
| None | Tirzepatide | View |
| None | Incretins | View |
| None | Glucagon-Like Peptide 1 | View |
| None | Gastric Inhibitory Polypeptide | View |
| None | Hormones | View |
| None | Hormones, Hormone Substitutes, and Hormone Antagonists | View |